These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8256796)

  • 41. Osteoporosis and its complications.
    Varacallo MA; Fox EJ
    Med Clin North Am; 2014 Jul; 98(4):817-31, xii-xiii. PubMed ID: 24994054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale for the use of clodronate in osteoporosis.
    Kanis JA; McCloskey EV; Sirtori P; Khan S; Fern D; Eyres K; Aaron J; Beneton MN
    Osteoporos Int; 1993; 3 Suppl 2():S23-8. PubMed ID: 8481595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Update on treatment of postmenopausal osteoporosis].
    Body JJ
    Rev Med Brux; 2008 Sep; 29(4):301-9. PubMed ID: 18949981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
    Papapoulos SE
    Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
    [No Abstract]   [Full Text] [Related]  

  • 46. [Fluorides and bisphosphonates in the treatment of osteoporosis].
    Ringe JD
    Orthopade; 2001 Jul; 30(7):456-61. PubMed ID: 11515184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bisphosphonate therapy in osteoporosis. Inhibition of trabecular perforation by aminobisphosphonate].
    Wüster C; Heilmann P
    Fortschr Med; 1997 Oct; 115(29):37-42. PubMed ID: 9445833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonates in osteoporosis: an introduction.
    Fleisch H
    Osteoporos Int; 1993; 3 Suppl 3():S3-5. PubMed ID: 8298201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of hip fractures: drug therapy.
    Lips P
    Bone; 1996 Mar; 18(3 Suppl):159S-163S. PubMed ID: 8777082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bisphosphonates in osteoporosis: recent clinical experience.
    McClung MR
    Expert Opin Pharmacother; 2000 Jan; 1(2):225-38. PubMed ID: 11249544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
    Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP
    Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
    Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
    J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
    Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
    Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Issues in designing and testing a "cure" for osteoporosis.
    Cummings S
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):408. PubMed ID: 15758283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.